Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer

被引：6

作者：

Kodama, Hirotake ^{[1
]}

Hatakeyama, Shingo ^{[1
]}

Narita, Shintaro ^{[2
]}

Takahashi, Masahiro ^{[3
]}

Sakurai, Toshihiko ^{[4
]}

Kawamura, Sadafumi ^{[5
]}

Hoshi, Senji ^{[6
]}

Ishida, Masanori ^{[7
]}

Kawaguchi, Toshiaki ^{[8
]}

Ishidoya, Shigeto ^{[9
]}

Shimoda, Jiro ^{[7
]}

Narita, Takuma ^{[1
]}

Sato, Hiromi ^{[2
]}

Mitsuzuka, Koji ^{[3
]}

Tochigi, Tatsuo ^{[5
]}

Tsuchiya, Norihiko ^{[4
]}

Arai, Yoichi ^{[5
]}

Habuchi, Tomonori ^{[2
]}

Ohyama, Chikara ^{[1
]}

机构：

[1] Hirosaki Univ, Dept Urol, Sch Med, Hirosaki, Aomori, Japan

[2] Akita Univ, Dept Urol, Sch Med, Akita, Japan

[3] Tohoku Univ, Dept Urol, Sch Med, Aoba Ku, Sendai, Miyagi, Japan

[4] Yamagata Univ, Dept Urol, Sch Med, Yamagata, Japan

[5] Miyagi Canc Ctr, Dept Urol, Natori, Miyagi, Japan

[6] Yamagata Prefectural Cent Hosp, Dept Urol, Yamagata, Japan

[7] Iwate Prefectural Isawa Hosp, Dept Urol, Mizusawa Ku, Oshu, Iwate, Japan

[8] Aomori Prefectural Cent Hosp, Dept Urol, Aomori, Japan

[9] Sendai City Hosp, Dept Urol, Taihaku Ku, Sendai, Miyagi, Japan

来源：

CLINICAL GENITOURINARY CANCER | 2019年 / 17卷 / 06期

基金：

日本学术振兴会;

关键词：

Castration-resistant prostate cancer; Prostate cancer; PSA; Sequential therapy; Survival; ANDROGEN DEPRIVATION; CHEMOTHERAPY; THERAPY;

D O I：

10.1016/j.clgc.2019.05.029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigate the effect of low prostate-specific antigen (PSA) on prognosis in 575 patients with metastatic castration-naive prostate cancer. The overall survival after castration-resistant prostate cancer diagnosis was significantly shorter in the PSA < 100 group than in the PSA >= 100 group. PSA < 100 ng/mL might be a poor prognostic factor in patients with metastatic castration-naive prostate cancer after castration-resistant prostate cancer. Introduction: This study aimed to investigate the effect of low prostate-specific antigen (PSA) on prognosis, as the association of initial PSA level with prognosis in patients with metastatic castration-naive prostate cancer (mCNPC) remains unclear. Patients and Methods: We evaluated 575 patients with mCNPC from 10 hospitals. Patients were stratified into 2 groups according to their initial PSA: PSA < 100 and PSA >= 100 groups. We compared castration-resistant prostate cancer (CRPC)-free survival, overall survival (OS), and OS from the CRPC diagnosis between the groups. Multivariate Cox regression analysis was performed to evaluate the effect of initial PSA level on prognosis. Results: Of the 575 patients, 196 (34%) patients belonged to the PSA < 100 group. No significant difference was found in patients' backgrounds except for PSA, the extent of disease, and high tumor burden between the groups. CRPC-free survival was significantly shorter in the PSA >= 100 group than in the PSA < 100 group. However, the OS after CRPC diagnosis was significantly shorter in the PSA < 100 group than that of the PSA >= 100 group. Multivariate analyses showed that PSA < 100 ng/mL was an independent factor for OS after CRPC, whereas no significant association was observed in the CRPC-free survival and OS. Conclusions: A significant effect of initial PSA < 100 ng/mL on OS after CRPC was observed. PSA < 100 ng/mL might be a poor prognostic factor in patients with mCNPC after CRPC.

引用

页码：E1091 / E1098

页数：8

共 50 条

[41] Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy
Sue Ping Thang
Violet, John
Sandhu, Shahneen
Iravani, Amir
Akhurst, Tim
Kong, Grace
Kumar, Aravind Ravi
Murphy, Declan G.
Williams, Scott G.
Hicks, Rodney J.
Hofman, Michael S.
EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (06): : 670 - 676
[42] Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration- resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study
Flippot, Ronan
Telli, Tugce
Velev, Maud
Flechon, Aude
De Vries-Brilland, Manon
Turpin, Leoa
Bergman, Andries
Turco, Fabio
Mahammedi, Hakim
Fendler, Wolfgang P.
Giraudet, Anne-Laure
Josset, Quentin
Montravers, Francoise
Vogel, Wouter
Gillessen, Silke
Vilei, Simona Berardi
Herrmann, Ken
Kryza, David
Paone, Gaetano
Hadaschik, Boris
Merlin, Charles
Dufour, Pierre-Alban
Bernard-Tessier, Alice
Naoun, Natacha
Patrikidou, Anna
Garcia, Camilo
Foulon, Stephanie
Pages, Arnaud
Fizazi, Karim
EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (05): : 1132 - 1140
[43] Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
Han, Sangwon
Woo, Sungmin
Kim, Yong-il
Lee, Jae-Lyun
Wibmer, Andreas G.
Schoder, Heiko
Ryu, Jin-Sook
Vargas, Hebert Alberto
DIAGNOSTICS, 2021, 11 (04)
[44] Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer
Niaz, Muhammad O.
Sun, Michael
Ramirez-Fort, Marigdalia
Niaz, Muhammad J.
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (02)
[45] Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review
Javaeed, Arslaan
Ghauri, Sanniya Khan
Ibrahim, Abdellatif
Doheim, Mohamed Fahmy
ONCOLOGY REVIEWS, 2020, 14 (01) : 64 - 71
[46] Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel
Olbert, Peter Jochen
Hegele, Axel
Kraeuter, Petra
Heidenreich, Axel
Hofmann, Rainer
Schrader, Andres Jan
ANTI-CANCER DRUGS, 2006, 17 (08) : 993 - 996
[47] Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer
Kawaguchi, Gen
Akazawa, Kohei
Ikeda, Taro
Ikeda, Yohei
Hara, Noboru
Nishiyama, Tsutomu
SAGE OPEN MEDICINE, 2023, 11
[48] The Utility of Prostate-Specific Antigen Screening and Prostate Cancer Treatment in Elderly Patients
Annelies Vellekoop
Stacy Loeb
Current Translational Geriatrics and Experimental Gerontology Reports, 2013, 2 (2): : 51 - 57
[49] The Utility of Prostate-Specific Antigen Screening and Prostate Cancer Treatment in Elderly Patients
Vellekoop, Annelies
Loeb, Stacy
CURRENT GERIATRICS REPORTS, 2013, 2 (02): : 51 - 57
[50] Utility of total prostate-specific antigen and free prostate-specific antigen index to detect prostate cancer in the asymptomatic patient
Rivera-Sanchez, Roberto
Parre-Mendez, Carlos
Luisa Caballero-Juradoc, Maria
Flores-Paz, Rocio
ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2022, 56 (01): : 11 - 15

← 1 2 3 4 5 →